Glenmark Pharmaceuticals Ltd.
|
Income Statement
|
|
You can view the
Income Statement
for the last 5 years.
Market Cap. (Rs.)
|
29416.70 Cr.
|
P/BV
|
3.11
|
Book Value (Rs.)
|
335.73
|
52 Week High/Low (Rs.)
|
1098/581
|
FV/ML
|
1/1
|
P/E(X)
|
98.97
|
Bookclosure
|
29/09/2023
|
EPS (Rs.)
|
10.53
|
Div Yield (%)
|
0.24
|
|
(Rs. in Crs.)
Months | 12 | 12 | 12 | 12 | 12 |
Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR | AR | AR |
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| | | | | |
| | | | | |
INCOME | | | | | |
Revenue From Operations [Net] | 12725.43 | 12174.20 | 10806.03 | 10397.23 | 9705.08 |
Other Operating Revenues | 264.68 | 130.71 | 137.90 | 243.74 | 160.38 |
Total Operating Revenues | 12990.11 | 12304.90 | 10943.93 | 10640.97 | 9865.47 |
| | | | | |
Other Income | 316.79 | 166.67 | 50.22 | 159.60 | 208.14 |
Total Revenue | 13306.90 | 12471.58 | 10994.15 | 10800.57 | 10073.61 |
| | | | | |
EXPENSES | | | | | |
Cost Of Materials Consumed | 3593.79 | 3278.76 | 3137.81 | 2541.47 | 2444.71 |
Purchase Of Stock-In Trade | 1268.26 | 1117.67 | 750.27 | 1029.08 | 976.30 |
Operating And Direct Expenses | 0.00 | 74.42 | 44.99 | 0.00 | 0.00 |
Changes In Inventories Of FG,WIP And Stock-In Trade | -325.09 | -11.14 | -189.25 | 128.08 | -58.67 |
Employee Benefit Expenses | 2780.96 | 2447.42 | 2343.71 | 2254.78 | 2056.07 |
Finance Costs | 349.58 | 298.10 | 353.11 | 377.32 | 334.59 |
Depreciation And Amortisation Expenses | 611.27 | 486.72 | 443.55 | 417.17 | 325.91 |
Other Expenses | 3393.83 | 3077.48 | 2772.03 | 2989.47 | 2861.26 |
Total Expenses | 11672.59 | 10769.42 | 9656.22 | 9737.37 | 8940.16 |
| | | | | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1634.31 | 1702.16 | 1337.93 | 1063.20 | 1133.45 |
| | | | | |
Exceptional Items | -765.85 | -260.91 | 44.55 | 32.88 | 167.18 |
Profit/Loss Before Tax | 868.45 | 1441.25 | 1382.48 | 1096.08 | 1300.63 |
| | | | | |
Tax Expenses-Continued Operations | | | | | |
Current Tax | 566.90 | 546.65 | 498.14 | 396.13 | 476.54 |
Deferred Tax | -75.85 | -99.05 | -85.75 | -76.02 | -100.91 |
Total Tax Expenses | 491.05 | 447.60 | 412.39 | 320.11 | 375.64 |
Profit/Loss After Tax And Before ExtraOrdinary Items | 377.40 | 993.65 | 970.09 | 775.97 | 924.99 |
| | | | | |
Profit/Loss From Continuing Operations | 377.40 | 993.65 | 970.09 | 775.97 | 924.99 |
| | | | | |
Profit/Loss For The Period | 377.40 | 993.65 | 970.09 | 775.97 | 924.99 |
| | | | | |
Minority Interest | -80.16 | -51.94 | -0.05 | 0.00 | 0.00 |
Consolidated Profit/Loss After MI And Associates | 297.25 | 941.71 | 970.04 | 775.97 | 924.99 |
| | | | | |
OTHER INFORMATION | | | | | |
| | | | | |
EARNINGS PER SHARE | | | | | |
Basic EPS (Rs.) | 10.53 | 33.37 | 34.38 | 27.50 | 32.78 |
Diluted EPS (Rs.) | 10.53 | 33.37 | 34.38 | 27.50 | 32.78 |
| | | | | |
DIVIDEND AND DIVIDEND PERCENTAGE | | | | | |
Equity Share Dividend | 70.54 | 70.54 | 70.54 | 68.03 | 68.03 |